TMO Thermo Fisher Scientific Inc Common Stock
Thermo Fisher Scientific Inc Common Stock 정보 위키백과 회사 개요
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).
더 보기
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).
It ranked 106th on the Fortune 500 list based on its 2025 annual revenue of $44.556 billion.
History
Predecessors and merger
Thermo Electron was co-founded in 1956 by George N. Hatsopoulos and Peter M Nomikos. Hatsopoulos received a PhD from MIT in mechanical engineering and Nomikos was a Harvard Business School graduate. The company focused on providing analytical and laboratory products.
Fisher Scientific was founded in 1902 by Chester G. Fisher from Pittsburgh. It focused on providing laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety, and education.
On May 8, 2006, Thermo Electron and Fisher Scientific announced that they would merge in a tax-free, stock-for-stock exchange; the merged company was named Thermo Fisher Scientific, and had about 30,000 employees, and reported US$9 billion in combined revenue. On November 9, 2006, the companies announced that the merger had been completed. However, the Federal Trade Commission ruled that this acquisition was anti-competitive regarding centrifugal evaporators, requiring Fisher to divest Genevac. In April 2007, Genevac was sold to Riverlake Partners LLC and the merger closed with FTC approval.
The company's products are sold under the brand names of Thermo Scientific, Fisher Scientific, and several other recognized brand names (e.g. Applied Biosystems, Invitrogen, Patheon, PPD, and Nalgene).
Acquisition history
In 1990, Thermo Fisher Scientific (then known as Thermo Instrument Systems) acquired mass spectrometer manufacturer Finnigan Instrument Corporation.
In 2003, the company (then Fisher Scientific International) acquired Perbio Science, a transaction that included brands such as Pierce Biotechnology, HyClone and Endogen.
In April 2006, BioImage was acquired by Thermo Fisher Scientific. The merger was complete in November 2006, and technology transfer to a US site was completed during 2007 and 2008. BioImage was established in 1993 as a drug discovery research unit led by Ole Thastrup within Novo Nordisk, from which it spun out of in 1999. It had specialized in developing and selling proprietary bioassays to biopharmaceutical companies and research institutions. It made broad patents covering Enhanced GFP (EGFP), GFP-based biosensors and any genetically encoded protein fusion to a luminophore, with subsequent monitoring of the protein's translocation within a cell as the primary readout for drug discovery assays.
In December 2010, Thermo Fisher Scientific announced its acquisition of Dionex for $2.1 billion.
In May 2011, Thermo Fisher Scientific Inc. bought Phadia to expand into the testing of allergies and autoimmune diseases for €2.47 billion ($3.5 billion) in cash.
In April 2013, after a competitive bidding with Hoffmann-La Roche, Thermo Fisher acquired Life Technologies Corporation for US$13.6 billion in a deal, adding further service lines related to advanced DNA sequencing and genetic testing. Life Technologies was originally formed in 2008 through a $6.7B merger of Invitrogen, a cell therapy, and Applied Biosystems. The company also acquired GIBCO (Grand Island Biological Company) as part of the Life Technologies acquisition.
In February 2015, the company announced it would acquire Advanced Scientifics for $300 million in a cash-deal. ASI designs manufactures, and delivers technologies used in bioprocessing. In June 2015, the company announced its intention to acquire Alfa Aesar, a global manufacturer of research chemicals for $405 million from Johnson Matthey, and the acquisition was completed at the end of September
In January 2016, the company announced it would acquire Affymetrix for $1.3 billion. On May 27, 2016, the company announced it would acquire FEI Company for $4.2 billion, a manufacturer of electron microscopes. This acquisition is anticipated to close in early 2017 and will contribute to the growth of Thermo's Analytical Instruments business group. In November the company announced it would acquire MTI-GlobalStem, a previously privately held company that develops reagents for cell transfection, neurobiology and stem cell research.
In February 2017, the company acquired Finesse Solutions, Inc., developer of scalable control automation systems and software for bioproduction after receiving early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction was completed a day later. In March, the company announced it would acquire Core Informatics, provider of cloud-based platforms supporting scientific data management. In August, the company acquired Patheon, a contract development and manufacturing organization serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. As of 2017, the company had revenues of $20.9 billion, and was a Fortune 500 company.
In September 2018, Thermo Fisher Scientific announced it had signed a definitive agreement with Becton, Dickinson and Company (BDX) to acquire their Advanced Bioprocessing business. This BD business had annualized revenue of approximately $100 million; as of October 16, 2018, it had been integrated into Thermo Fisher's Life Sciences Solutions Segment.
In March 2019, Thermo Fisher Scientific announced its entry into the gene therapy manufacturing market with a $1.7 billion cash acquisition for Brammer Bio. In May 2019, Thermo Fisher Scientific partnered with MMJ International Holdings to manufacture drug products developed by MMJ for the treatment of multiple sclerosis and Huntington's disease. In June, the business announced it would acquire mass spectrometry software provider, HighChem.
In March 2020, Thermo Fisher Scientific received emergency use authorization from the FDA for a test for SARS-CoV-2 to help mitigate the COVID-19 pandemic. Thermo Fisher also partnered with its biopharma customers, including Pfizer and Moderna, to
support the development and production of new mRNA-based COVID-19 vaccines.
In March 2020, Thermo Fisher Scientific agreed to purchase Qiagen, a molecular diagnostics company, for $10.1 billion. In July, the offer for Qiagen was raised from €39 to €43 per share (€11.3 billion in total). On August 13, the company announced that its offer to acquire all of the ordinary share had lapsed, and it terminated the acquisition agreement.
In August 2020, Thermo Fisher Scientific opened its new Lenexa facility aimed at boosting the production and manufacturing of COVID-19 testing supplies. In December the business announced it would acquire Phitonex, Inc.
In January 2021, Thermo Fisher Scientific announced it had acquired Belgium-based viral vector manufacturer, Henogen SA, from Groupe Novasep SAS for €725 million in cash and point-of-care molecular diagnostics provider Mesa Biotech, Inc. for up to $550 million.
In April 2021, Thermo Fisher Scientific announced the acquisition of PPD, Inc., a contract research organization, for a total cash purchase price of $17.4 billion-plus the assumption of approximately $3.5 billion of net debt. PPD generated $4.7 billion in revenue during FY 2020, and this transaction, which values their company at approximately $20.9 billion. In November, the business announced it would acquire PharmaFluidics and its μPAC range of micro-chip-based chromatography products.
In January 2022, Thermo Fisher Scientific acquired PeproTech, a developer and manufacturer of recombinant proteins, for $1.85 billion. PeproTech became part of Thermo Fisher’s biosciences business and was integrated into the Life Sciences Solutions Segment.
In October 2022, the company agreed to buy British diagnostics firm, The Binding Site Group, in an all-cash deal for US$2.6 billion from Nordic Capital. The acquisition completed in January 2023.
In July 2023, the business announced it would acquire CorEvitas, LLC from Audax Private Equity for more than $900 million in cash. In August 2023, it was announced Thermo Fisher had completed the acquisition for $912.5 million (in cash).
In October 2023, Thermo Fisher Scientific acquired Olink Holding for $3.1 billion.
In February 2025, Thermo Fisher announced the acquisition of Solventum’s purification and filtration business for $4.1 billion.
In July 2025, Thermo Fisher added drug manufacturing capabilities in the United States through its purchase of a sterile fill-finish and packaging plant from Sanofi in Ridgefield, New Jersey.
In October 2025, Thermo Fisher announced a deal to acquire Clario Holdings—an endpoint data management solutions provider—for $8.88 billion in cash from a shareholder group including Novo Holding. The transaction was expected to close mid-2026.
Leadership
Marc N. Casper has been Chief Executive Officer of Thermo Fisher Scientific since October 2009, and was elected Chairman of the Board in February 2020. He also served as President from 2009 until March 2026. He joined the company in 2001 as President of the Life Sciences sector of Thermo Electron. Casper was named Senior Vice President in 2003, and in 2005 assumed responsibility for all of the company’s operating divisions. After the merger creating Thermo Fisher Scientific in 2006, he was named Executive Vice President and President of its Analytical Technologies business, and in 2008 he became the company’s Chief Operating Officer.
Prior to joining Thermo Fisher, Casper served as President, Chief Executive Officer and a Director of Kendro Laboratory Products. Previously, he worked for clinical diagnostics provider Dade Behring Inc., serving as President–Americas. He began his career as a strategy consultant at Bain & Company and later joined Bain Capital.
Partnerships
In September 2017, Thermo Fisher Scientific signed an agreement with the Institute of Pathology Heidelberg (IPH) to establish its Center of Molecular Pathology at Heidelberg University Hospital as the newest member of the Next Generation Sequencing Companion Dx Center of Excellence Program (COEP). The initiative focuses on establishing strategic collaborations with leading, European-based organizations that can lead studies using Thermo Fisher's Oncomine portfolio of research panels destined for development as companion diagnostics to help drive precision oncology in the region.
In 2021, Thermo Fisher announced the construction of a cell therapy development, manufacturing and collaboration center in cooperation with University of California, San Francisco on the school's Mission Bay campus.
In February 2022, Thermo Fisher Scientific announced a 15-year strategic collaboration
agreement with Moderna, Inc. The collaboration was designed to scale up the
manufacturing of Moderna’s COVID-19 vaccine and other investigational mRNA
products.
In May 2023, Thermo Fisher partnered with Pfizer, with plans to work together on expanding testing capabilities for lung and breast cancer patients.
In November 2023, Thermo Fisher partnered with Flagship Pioneering, a biotechnology company. Together, they plan to create companies in the biotechnology field.
In January 2025, Thermo Fisher partnered with the UK Biobank Pharma Proteomics Project (UKB-PPP) to support the world’s largest human proteomics study. Using the Olink Explore platform, UKB-PPP seeks to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose, and treat diseases.
In February 2025, Thermo Fisher entered a 10-year virtual power purchase agreement (VPPA) with X-ELIO to secure 118 megawatts of solar energy, moving its European operations closer to a 100% renewable electricity goal.
In June 2025, Thermo Fisher partnered with the Regeneron Genetics Center which selected the Olink Explore platform for large-scale proteomics investigation involving nearly 200,000 patient samples aiming to unlock new insights into the dynamic biology and mechanisms of human disease.
Controversies
Xinjiang and Tibet
In February 2019, Thermo Fisher Scientific announced that it would stop selling its equipment in Xinjiang. In June 2020, Thermo Fisher Scientific was reported to sell its equipment to security services in China for use in what was alleged as part of a genetic surveillance program. A report from the Australian Strategic Policy Institute found that Thermo Fisher Scientific collaborated with the Chinese Ministry of Public Security to develop a Huaxia PCR amplification kit specifically to identify the genotypes of Uyghur, Tibetan and Hui ethnic minorities. In June 2021, The New York Times reported that, despite bans, Thermo Fisher Scientific equipment continued to be sold to police in Xinjiang.
In 2022, following reports that Thermo Fisher Scientific had sold products to police in the Tibet Autonomous Region, the Inter-Parliamentary Alliance on China called on governments to "investigate and suspend commercial activities with companies providing the PRC government with technologies to carry out biometric surveillance in the Uyghur Region, Tibet and elsewhere in the PRC, including the PRC state backed BGI Group and US firm Thermo Fisher." Thermo Fisher Scientific subsequently halted sales of DNA collection kits in Tibet.
HeLa cells
In October 2021 the estate of Henrietta Lacks sued to get past and future payment for the alleged and widely known unauthorized sale by Thermo Fisher Scientific of her HeLa cells which are essential in many types of research. Over 50 million tons of her cells have been produced and used in over 60,000 scientific studies touching virtually every realm of medicine, including the development of polio vaccines, gene mapping, in-vitro fertilization, and multitudes more.
In May 2022, it was announced Thermo Fisher Scientific went to court to seek a dismissal of the lawsuit. In late July 2023, with the motion to dismiss still outstanding, the court ordered the parties to attend a settlement conference. Soon after that, settlement of the suit, with undisclosed terms, was announced.
Mexican plant
In 2013, Opengate Capital Group LLC filed suit against Thermo Fisher Scientific for selling it a manufacturing plant controlled by the Gulf Cartel. According to Opengate Capital, the company withheld important documents and pressured employees into concealing the presence of the drug cartel.
Image manipulation
In May 2026, scientists found that a large number of images from Thermo Fisher Scientific's catalog had been manipulated, with sections of the images blanked out and duplicated with the same part of the picture copied into multiple places. The images were claimed to validate the effectiveness of antibody products which have uses including Western blots.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
TMO 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
TMO 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
10년 성과 매출, 순이익, 마진 및 EPS 추세
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
배당금 배당 수익률, 지급 비율, 배당 이력, 5년 CAGR
| 배당락일 | 금액 |
|---|---|
| 2026년 6월 15일 | $0.4700 |
| 2026년 3월 13일 | $0.4700 |
| 2025년 12월 15일 | $0.4300 |
| 2025년 9월 15일 | $0.4300 |
| 2025년 6월 13일 | $0.4300 |
| 2025년 3월 14일 | $0.4300 |
| 2024년 12월 13일 | $0.3900 |
| 2024년 9월 13일 | $0.3900 |
| 2024년 6월 14일 | $0.3900 |
| 2024년 3월 14일 | $0.3900 |
| 2023년 12월 14일 | $0.3500 |
| 2023년 9월 14일 | $0.3500 |
| 2023년 6월 14일 | $0.3500 |
| 2023년 3월 14일 | $0.3500 |
| 2022년 12월 14일 | $0.3000 |
| 2022년 9월 14일 | $0.3000 |
| 2022년 6월 14일 | $0.3000 |
| 2022년 3월 15일 | $0.3000 |
| 2021년 12월 14일 | $0.2600 |
| 2021년 9월 14일 | $0.2600 |
TMO 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
- 적극 매수 11 30.6%
- 매수 18 50.0%
- 보유 7 19.4%
- 매도 0 0.0%
- 적극 매도 0 0.0%
12개월 목표 주가
26 명의 애널리스트 · 2026-08-14실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 6월 30일 | $6.03 | $5.77 | 0.26% |
| 2026년 3월 31일 | $5.44 | $5.29 | 0.15% |
| 2025년 12월 31일 | $6.57 | $6.51 | 0.06% |
| 2025년 9월 30일 | $5.79 | $5.55 | 0.24% |
| 2025년 6월 30일 | $5.36 | $5.28 | 0.08% |
| 2025년 3월 31일 | $5.15 | $5.15 | -0.00% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| TMO | $257.86B | 32.7 | 3.9% | 15.0% | 13.0% | — |
| DHR | $161.82B | 45.3 | 2.9% | 14.7% | 7.1% | 59.1% |
| A | $41.43B | 32.0 | 6.7% | 18.8% | 20.6% | — |
| IQV | $38.23B | 28.8 | 5.9% | 8.3% | 21.6% | — |
| WAT | $22.62B | 35.3 | 7.0% | 20.3% | 27.2% | — |
| ILMN | $20.65B | 24.8 | -0.66% | 19.6% | 34.1% | 66.1% |
| MTD | $28.38B | 33.2 | 4.0% | 21.6% | -615.5% | 59.4% |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 17
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.56B | $42.88B | $42.86B | $44.91B | $39.21B | $32.22B | $25.54B | $24.36B | · | $18.27B | $16.96B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | · | $8.21B | $7.58B | |
| R&D Expense | $1.40B | $1.39B | $1.34B | $1.47B | $1.41B | $1.18B | $1.00B | $967M | · | $754M | $692M | |
| SG&A Expense | $8.73B | $8.60B | $8.45B | $8.99B | $8.01B | $6.93B | $6.14B | $6.06B | · | $4.97B | $4.61B | |
| Operating Expenses | $36.81B | $35.54B | $36.00B | $36.52B | $29.18B | $24.42B | $20.95B | $20.57B | · | $15.82B | $14.63B | |
| Operating Income | $7.75B | $7.34B | $6.86B | $8.39B | $10.03B | $7.79B | $4.59B | $3.78B | · | $2.46B | $2.34B | |
| Interest Expense | · | · | $1.38B | $726M | $536M | $553M | $676M | $667M | · | $469M | $415M | |
| Interest Income | $993M | $1.08B | $879M | $272M | $43M | $65M | $224M | $137M | · | $48M | $31M | |
| Other Non-op | $-12M | $12M | $-65M | $-104M | $-694M | $-76M | $-70M | $9M | · | $-13M | $-16M | |
| Pretax Income | $7.31B | $7.04B | $6.30B | $7.83B | $8.84B | $7.23B | $4.07B | $3.26B | · | $2.02B | $1.94B | |
| Income Tax | $547M | $657M | $284M | $703M | $1.11B | $850M | $374M | $324M | · | $-1M | $-44M | |
| Net Income | $6.70B | $6.33B | $6.00B | $6.96B | $7.73B | $6.38B | $3.70B | · | · | · | · | |
| EPS (Basic) | $17.77 | $16.58 | $15.52 | $17.75 | $19.62 | $16.09 | $9.24 | $7.31 | · | $5.12 | $4.96 | |
| EPS (Diluted) | $17.74 | $16.53 | $15.45 | $17.63 | $19.46 | $15.96 | $9.17 | $7.24 | · | $5.09 | $4.92 | |
| Shares (Basic) | 377,000,000 | 382,000,000 | 386,000,000 | 392,000,000 | 394,000,000 | 396,000,000 | 400,000,000 | 402,000,000 | · | 395,000,000 | 399,000,000 | |
| Shares (Diluted) | 378,000,000 | 383,000,000 | 388,000,000 | 394,000,000 | 397,000,000 | 399,000,000 | 403,000,000 | 406,000,000 | · | 397,000,000 | 402,000,000 | |
| EBITDA | $7.75B | $7.34B | $6.86B | $8.39B | $10.03B | $7.79B | $4.59B | $6.05B | · | $4.21B | $4.02B |
대차대조표 28
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.85B | $4.01B | $8.08B | $8.52B | $4.48B | $10.32B | $2.40B | $2.10B | · | $786M | $452M | |
| Short-term Investments | $253M | $1.56B | $3M | · | · | · | · | · | · | · | · | |
| Receivables | $8.90B | $8.19B | $8.22B | $8.12B | $7.98B | $5.74B | $4.35B | $4.14B | $3.87B | $3.05B | $2.54B | |
| Inventory | $5.42B | $4.98B | $5.09B | $5.63B | $5.05B | $4.03B | $3.37B | $3.00B | $2.72B | $2.21B | $1.99B | |
| Other Current Assets | $2.61B | $1.96B | $1.76B | $1.64B | $1.64B | $1.13B | $1.17B | $922M | $1.47B | $595M | $534M | |
| Current Assets | $28.71B | $22.14B | $24.59B | $25.23B | $20.11B | $21.96B | $11.89B | $10.62B | · | $7.02B | $5.74B | |
| PP&E (Net) | $10.56B | $9.31B | $9.45B | $9.28B | $8.33B | $5.91B | $4.75B | $4.17B | · | $2.58B | $2.45B | |
| PP&E (Gross) | $18.38B | $16.06B | $15.52B | $14.27B | $12.59B | $9.58B | $7.76B | $6.82B | · | $4.42B | $4.11B | |
| Accum. Depreciation | $7.82B | $6.75B | $6.08B | $4.99B | $4.26B | $3.67B | $3.02B | $2.65B | · | $1.84B | $1.66B | |
| Goodwill | $49.36B | $45.85B | $44.02B | $41.20B | $41.92B | $26.04B | $25.71B | $25.35B | · | $21.33B | $18.83B | |
| Intangibles | $15.84B | $15.53B | $16.67B | $17.44B | $20.11B | $12.69B | $14.01B | $14.98B | · | $13.97B | $12.76B | |
| Other Non-current Assets | $5.87B | $4.49B | $4.00B | $4.01B | $4.64B | $2.46B | $2.01B | $1.12B | $1.17B | $1.01B | $1.06B | |
| Total Assets | $110.34B | $97.32B | $98.73B | $97.15B | $95.12B | $69.05B | $58.38B | $56.23B | · | $45.91B | $40.83B | |
| Accounts Payable | $3.62B | $3.08B | $2.87B | $3.38B | $2.87B | $2.17B | $1.92B | $1.61B | · | $926M | $822M | |
| Short-term Debt | · | · | · | · | · | · | · | $693M | · | $953M | $50M | |
| Current Liabilities | $15.19B | $13.33B | $14.01B | $17.01B | $13.44B | $10.30B | $6.20B | $6.15B | · | $4.87B | $4.15B | |
| Capital Leases | $1.20B | $1.24B | $1.24B | $1.31B | $1.20B | $626M | $571M | · | · | · | · | |
| Deferred Tax | $1.49B | $1.27B | $1.92B | $2.85B | $3.84B | $1.79B | $2.19B | $2.27B | $2.71B | $2.56B | $2.62B | |
| Other Non-current Liabilities | $4.27B | $3.99B | $4.64B | $4.24B | $4.54B | $3.33B | $3.24B | $2.52B | $2.64B | $1.57B | $1.29B | |
| Long-term Debt | $39.17B | $31.07B | $34.73B | $34.28B | $34.67B | $21.73B | $17.75B | $18.99B | · | · | · | |
| Total Debt | · | · | · | · | · | $19.11B | $17.08B | $693M | · | $953M | $50M | |
| Common Stock | $445M | $444M | $442M | $441M | $439M | $437M | $434M | $432M | · | $415M | $412M | |
| Retained Earnings | $59.16B | $53.10B | $47.36B | $41.91B | $35.43B | $28.12B | $22.09B | $18.70B | $16.03B | $13.93B | $12.14B | |
| Treasury Stock | $22.31B | $19.23B | $15.13B | $12.02B | $8.92B | $6.82B | $5.24B | $3.67B | · | $2.31B | $1.01B | |
| AOCI | $-2.45B | $-2.70B | $-3.22B | $-3.10B | $-2.33B | $-2.81B | $-2.68B | $-2.50B | $-2.09B | $-2.64B | $-2.00B | |
| Stockholders' Equity | $53.41B | $49.58B | $46.73B | $43.98B | $40.79B | $34.51B | $29.68B | $27.59B | · | $21.54B | $21.35B | |
| Liabilities + Equity | $110.34B | $97.32B | $98.73B | $97.15B | $95.12B | $69.05B | $58.38B | $56.23B | · | $45.91B | $40.83B | |
| Shares Outstanding | 445,000,000 | 444,000,000 | 442,000,000 | 441,000,000 | 439,000,000 | 437,000,000 | 434,000,000 | · | · | · | · |
현금 흐름 19
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $2.27B | · | $1.76B | $1.69B | |
| Stock-based Comp | $310M | $301M | $278M | $307M | $230M | $196M | $181M | $181M | · | $133M | $125M | |
| Deferred Tax | $-639M | $-1.21B | $-1.30B | $-997M | $-645M | $-269M | $-499M | $-474M | · | $-639M | $-600M | |
| Amort. of Intangibles | $1.73B | $1.95B | $2.34B | $2.40B | $1.76B | $1.67B | $1.71B | $1.74B | · | $1.38B | $1.31B | |
| Restructuring | $197M | $97M | $194M | $68M | $37M | $51M | $52M | $88M | · | $167M | $90M | |
| Operating Cash Flow | $7.82B | $8.67B | $8.41B | $9.15B | $9.31B | $8.29B | $4.97B | $4.54B | · | $3.26B | $2.94B | |
| CapEx | $1.52B | $1.40B | $1.48B | $2.24B | $2.52B | $1.47B | $926M | $758M | · | $444M | $423M | |
| Investing Cash Flow | $-4.05B | $-5.84B | $-5.14B | $-2.16B | $-21.93B | $-1.51B | $-1.49B | $-1.25B | · | $-5.52B | $-1.09B | |
| Debt Issued | $7.76B | $1.20B | $5.94B | $3.19B | $18.14B | $3.46B | $5.64B | $690M | · | $7.60B | $1.80B | |
| Net Debt Issued | $5.35B | $-2.40B | $160M | $2.82B | $6.40B | $2.75B | $-722M | $-1.36B | · | $3.27B | $-1.98B | |
| Stock Issued | · | · | · | · | · | · | $0 | $0 | · | $0 | $0 | |
| Stock Repurchased | $3.00B | $4.00B | $3.00B | $3.00B | $2.00B | $1.50B | $1.50B | $500M | · | $1.25B | $500M | |
| Net Stock Activity | $-3.00B | $-4.00B | $-3.00B | $-3.00B | $-2.00B | $-1.50B | $-1.50B | $-500M | · | $-1.25B | $-500M | |
| Dividends Paid | $636M | $583M | $523M | $455M | $395M | $337M | $297M | $266M | · | $238M | $241M | |
| Financing Cash Flow | $1.80B | $-6.79B | $-3.62B | $-2.81B | $6.58B | $959M | $-3.12B | $-2.24B | · | $2.76B | $-2.62B | |
| Net Change in Cash | $5.84B | $-4.06B | $-440M | $4.05B | $-5.84B | $7.91B | $305M | $756M | · | $345M | $-898M | |
| Taxes Paid | $1.78B | $1.83B | $1.48B | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $6.29B | $7.27B | $6.93B | $6.91B | $6.79B | $6.82B | $4.05B | $3.79B | · | $2.71B | $2.39B | |
| Levered FCF | · | · | $5.61B | $6.25B | $6.32B | $6.33B | $3.43B | $3.18B | · | $2.24B | $1.97B |
수익성 7
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 17.4% | 17.1% | 16.0% | 18.7% | 25.6% | 24.2% | 18.0% | 15.5% | · | 13.4% | 13.8% | |
| Net Margin | 15.0% | 14.8% | 13.9% | 15.5% | 19.7% | · | · | · | · | · | · | |
| Pretax Margin | 16.4% | 16.4% | 14.7% | 17.4% | 22.6% | 22.4% | 15.9% | 13.4% | · | 11.1% | 11.4% | |
| EBITDA Margin | 17.4% | 17.1% | 16.0% | 18.7% | 25.6% | 24.2% | 18.0% | 24.8% | · | 23.0% | 23.7% | |
| ROA | 6.5% | 6.4% | 6.1% | 7.2% | 9.4% | · | · | · | · | · | · | |
| ROE | 13.0% | 13.2% | 13.1% | 16.4% | 19.9% | · | · | · | · | · | · | |
| ROIC | 13.4% | 13.4% | 14.0% | 17.4% | 21.5% | 12.8% | 8.9% | 12.0% | · | 10.9% | 11.2% |
유동성 및 지급능력 5
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 1.7 | 1.8 | 1.5 | 1.5 | 2.1 | 1.9 | 1.7 | · | 1.4 | 1.4 | |
| Quick Ratio | 1.3 | 1.0 | 1.2 | 1.0 | 0.9 | 1.6 | 1.1 | 1.0 | · | 0.8 | 0.7 | |
| Debt / Equity | · | · | · | · | · | 0.6 | 0.6 | 0.0 | · | 0.0 | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | 0.6 | 0.6 | · | · | · | · | |
| Interest Coverage | · | · | 5.0 | 11.6 | 18.7 | 14.1 | 6.8 | 5.7 | · | 5.2 | 5.6 |
효율성 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | · | 0.4 | 0.4 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | · | 3.9 | 3.9 | |
| Receivables Turnover | 5.2 | 5.2 | 5.2 | 5.6 | 5.7 | 6.4 | 6.0 | 6.1 | · | 6.5 | 6.8 |
성장률 10
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 3.9% | 0.05% | -4.6% | 14.5% | 21.7% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -0.27% | 3.0% | 10.0% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.7% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 7.3% | 7.0% | -12.4% | -9.4% | 21.9% | · | · | · | · | · | · | |
| EPS CAGR 3Y | 0.21% | -5.3% | -1.1% | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 2.1% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 5.8% | 5.7% | -13.9% | -9.9% | 21.2% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -1.2% | -6.4% | -2.0% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 1.0% | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 13.5% | · | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM) 12
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $44.56B | $42.88B | $42.86B | $44.91B | $39.21B | $32.22B | $25.54B | $24.36B | · | $18.27B | $16.96B | |
| Net Income TTM | $6.70B | $6.33B | $6.00B | $6.96B | $7.73B | $6.38B | $3.70B | $1.48B | · | $1.48B | $1.48B | |
| Market Cap | $257.86B | $230.98B | $234.61B | $242.85B | · | · | · | · | · | · | · | |
| P/E | 32.7 | 31.5 | 34.4 | 31.2 | 34.3 | 29.2 | 35.4 | 30.9 | · | 27.7 | 28.8 | |
| P/S | 5.8 | 5.4 | 5.5 | 5.4 | · | · | · | · | · | · | · | |
| P/B | 4.8 | 4.7 | 5.0 | 5.5 | · | · | · | · | · | · | · | |
| P / Cash Flow | 33.0 | 26.7 | 27.9 | 26.5 | · | · | · | · | · | · | · | |
| P / FCF | 41.0 | 31.8 | 33.9 | 35.1 | · | · | · | · | · | · | · | |
| Dividend Yield | 0.25% | 0.25% | 0.22% | 0.19% | · | · | · | · | · | · | · | |
| Earnings Yield | 3.1% | 3.2% | 2.9% | 3.2% | 2.9% | 3.4% | 2.8% | 3.2% | · | 3.6% | 3.5% | |
| Payout Ratio | 9.5% | 9.2% | 8.8% | 6.5% | 5.1% | · | · | · | · | · | · | |
| Annual Payout | $636M | $583M | $523M | $455M | $395M | $337M | $297M | $266M | · | $238M | $241M |
손익계산서 16
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.99B | $11.01B | $12.21B | $11.12B | $10.86B | $10.36B | $11.39B | $10.60B | $10.54B | $10.35B | $10.89B | $10.57B | $10.71B | $11.45B | |
| R&D Expense | $364M | $336M | $357M | $346M | $352M | $342M | $374M | $346M | $339M | $331M | $327M | $319M | $346M | $391M | |
| SG&A Expense | $2.33B | $2.18B | $2.35B | $2.16B | $2.14B | $2.08B | $2.20B | $2.10B | $2.11B | $2.18B | $2.13B | $2.05B | $2.12B | $2.30B | |
| Operating Expenses | $9.91B | $9.14B | $9.96B | $9.18B | $9.02B | $8.65B | $9.38B | $8.76B | $8.72B | $8.68B | $9.03B | $8.71B | $9.15B | $9.59B | |
| Operating Income | $2.09B | $1.86B | $2.25B | $1.94B | $1.83B | $1.72B | $2.02B | $1.84B | $1.82B | $1.66B | $1.85B | $1.86B | $1.56B | $1.86B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $363M | · | $359M | $300M | · | |
| Interest Income | $207M | $233M | $259M | $234M | $297M | $203M | $227M | $277M | $295M | $279M | $309M | $246M | $146M | $150M | |
| Other Non-op | $31M | $-9M | $6M | $-2M | $-19M | $3M | $13M | $-16M | $5M | $10M | $-33M | $14M | $-46M | $35M | |
| Pretax Income | $1.92B | $1.73B | $2.15B | $1.83B | $1.71B | $1.62B | $1.94B | $1.74B | $1.76B | $1.59B | $1.74B | $1.76B | $1.36B | $1.78B | |
| Income Tax | $167M | $70M | $153M | $207M | $92M | $95M | $149M | $99M | $128M | $281M | $133M | $53M | $46M | $173M | |
| Net Income | $1.74B | $1.65B | $1.96B | $1.62B | $1.62B | $1.51B | $1.83B | $1.63B | $1.55B | $1.33B | $1.65B | $1.70B | $1.29B | $1.57B | |
| EPS (Basic) | $4.68 | $4.44 | $5.22 | $4.28 | $4.28 | $3.99 | $4.80 | $4.26 | $4.05 | $3.47 | $4.21 | $4.44 | $3.34 | $4.03 | |
| EPS (Diluted) | $4.68 | $4.43 | $5.21 | $4.27 | $4.28 | $3.98 | $4.78 | $4.25 | $4.04 | $3.46 | $4.20 | $4.42 | $3.32 | $4.01 | |
| Shares (Basic) | 371,000,000 | 372,000,000 | -757,000,000 | 378,000,000 | 378,000,000 | 378,000,000 | -764,000,000 | 382,000,000 | 382,000,000 | 382,000,000 | 0 | 386,000,000 | 386,000,000 | 0 | |
| Shares (Diluted) | 371,000,000 | 373,000,000 | -757,000,000 | 378,000,000 | 378,000,000 | 379,000,000 | -768,000,000 | 384,000,000 | 383,000,000 | 384,000,000 | 0 | 388,000,000 | 388,000,000 | -1,000,000 | |
| EBITDA | $2.09B | $1.86B | · | $1.94B | $1.83B | $1.72B | · | $1.84B | $1.82B | $1.66B | · | $1.86B | $1.56B | · |
대차대조표 26
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.06B | $3.25B | $9.85B | $1.98B | $4.58B | $4.13B | $4.01B | $4.64B | $7.07B | $5.50B | · | $6.15B | $3.48B | · | |
| Short-term Investments | $0 | $2M | $253M | $1.56B | $1.81B | $1.81B | $1.56B | $2.00B | $1.75B | $1.75B | · | · | · | · | |
| Receivables | $9.45B | $9.20B | $8.90B | $8.91B | $8.59B | $8.46B | $8.19B | $8.26B | $7.94B | $7.93B | · | $8.37B | $7.92B | · | |
| Inventory | $5.63B | $5.50B | $5.42B | $5.75B | $5.56B | $5.22B | $4.98B | $5.43B | $5.20B | $5.13B | · | $5.40B | $5.66B | · | |
| Other Current Assets | $2.54B | $2.68B | $2.61B | $2.47B | $2.60B | $2.39B | $1.96B | $1.91B | $2.02B | $1.90B | · | $1.70B | $1.77B | · | |
| Current Assets | $23.36B | $22.32B | $28.71B | $22.30B | $24.58B | $23.38B | $22.14B | $23.78B | $25.48B | $23.64B | · | $23.09B | $20.21B | · | |
| PP&E (Net) | $10.76B | $10.66B | $10.56B | $10.18B | $9.63B | $9.33B | $9.31B | $9.41B | $9.28B | $9.32B | · | $9.17B | $9.35B | · | |
| PP&E (Gross) | · | · | $18.38B | · | · | · | $16.06B | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $7.82B | · | · | · | $6.75B | · | · | · | · | · | · | · | |
| Goodwill | $54.83B | $55.19B | $49.36B | $49.29B | $47.25B | $46.49B | $45.85B | $46.73B | $43.84B | $43.84B | $44.02B | $43.58B | $43.14B | $41.20B | |
| Intangibles | $18.61B | $19.15B | $15.84B | $16.24B | $15.15B | $15.32B | $15.53B | $16.26B | $15.52B | $16.05B | · | $17.09B | $17.97B | · | |
| Other Non-current Assets | $5.62B | $5.97B | $5.87B | $5.02B | $4.62B | $4.52B | $4.49B | $4.18B | $4.38B | $4.24B | · | $4.12B | $3.98B | · | |
| Total Assets | $113.17B | $113.28B | $110.34B | $103.02B | $101.23B | $99.04B | $97.32B | $100.36B | $98.50B | $97.09B | $98.73B | $97.06B | $94.66B | $97.15B | |
| Accounts Payable | $3.27B | $3.34B | $3.62B | $3.12B | $2.98B | $3.05B | $3.08B | $2.61B | $2.55B | $2.56B | · | $2.51B | $2.80B | · | |
| Current Liabilities | $15.07B | $14.62B | $15.19B | $14.89B | $12.72B | $13.17B | $13.33B | $14.60B | $14.77B | $13.94B | · | $14.16B | $15.88B | · | |
| Capital Leases | · | · | $1.20B | · | · | · | $1.24B | · | · | · | · | · | · | · | |
| Deferred Tax | $1.58B | $2.11B | $1.49B | $842M | $624M | $1.04B | $1.27B | $1.12B | $1.52B | $1.81B | · | $2.62B | $2.98B | · | |
| Other Non-current Liabilities | $4.54B | $4.42B | $4.27B | $4.28B | $4.27B | $3.97B | $3.99B | $4.34B | $4.39B | $4.57B | · | $4.33B | $4.23B | · | |
| Long-term Debt | $42.28B | $42.95B | $39.17B | $35.48B | $35.03B | $33.99B | $31.07B | $35.11B | $35.20B | $35.39B | · | $35.08B | $35.05B | · | |
| Common Stock | $446M | $445M | $445M | $445M | $444M | $444M | $444M | $444M | $443M | $443M | · | $442M | $441M | · | |
| Retained Earnings | $62.19B | $60.63B | $59.16B | $57.35B | $55.90B | $54.45B | $53.10B | $51.42B | $49.94B | $48.54B | · | $45.87B | $43.06B | · | |
| Treasury Stock | $26.37B | $25.36B | $22.31B | $22.31B | $21.27B | $21.27B | $19.23B | $18.23B | $18.19B | $18.19B | · | $15.12B | $15.08B | · | |
| AOCI | $-2.46B | $-2.50B | $-2.45B | $-2.80B | $-2.80B | $-2.34B | $-2.70B | $-2.48B | $-2.41B | $-2.76B | · | $-3.03B | $-3.05B | · | |
| Stockholders' Equity | $52.68B | $51.93B | $53.41B | $51.02B | $50.51B | $49.39B | $49.58B | $48.99B | $47.43B | $45.52B | · | $45.33B | $42.26B | · | |
| Liabilities + Equity | $113.17B | $113.28B | $110.34B | $103.02B | $101.23B | $99.04B | $97.32B | $100.36B | $98.50B | $97.09B | · | $97.06B | $94.66B | · | |
| Shares Outstanding | 446,000,000 | 445,000,000 | 445,000,000 | 445,000,000 | 444,000,000 | 444,000,000 | 444,000,000 | 444,000,000 | 443,000,000 | 443,000,000 | 442,000,000 | 442,000,000 | 441,000,000 | 441,000,000 |
현금 흐름 16
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $82M | $83M | $84M | $70M | $81M | $75M | $79M | $68M | $84M | $70M | $61M | $67M | $76M | $75M | |
| Deferred Tax | $-208M | $-258M | $89M | $-127M | $-322M | $-279M | $-202M | $-400M | · | · | · | · | · | · | |
| Amort. of Intangibles | $485M | $430M | $436M | $435M | $430M | $429M | $438M | $449M | $514M | $551M | $563M | $584M | $606M | $592M | |
| Restructuring | $38M | $34M | $36M | $62M | $56M | $43M | $20M | $26M | $26M | $25M | $19M | $38M | $50M | $37M | |
| Operating Cash Flow | $2.12B | $1.19B | $3.46B | $2.24B | $1.40B | $723M | $3.29B | $2.17B | $1.96B | $1.25B | $3.72B | $2.41B | $729M | $3.49B | |
| CapEx | $450M | $376M | $465M | $404M | $294M | $362M | $480M | $272M | $301M | $347M | $405M | $332M | $458M | $550M | |
| Investing Cash Flow | $164M | $-8.96B | $891M | $-4.12B | $-288M | $-527M | $20M | $-3.58B | $-253M | $-2.03B | $-376M | $-1.18B | $-3.14B | $-525M | |
| Debt Issued | $0 | $5.24B | $4.92B | $0 | $0 | $2.84B | $0 | $0 | $-1M | $1.21B | $2.48B | $3.47B | $0 | $3.19B | |
| Net Debt Issued | · | $3.83B | · | · | · | $2.00B | · | · | · | $1.21B | · | · | $0 | · | |
| Stock Repurchased | $1.00B | $3.00B | $37M | $963M | $0 | $2.00B | $1.00B | $0 | $0 | $3.00B | $0 | $0 | $3.00B | $1.00B | |
| Net Stock Activity | · | $-3.00B | · | · | · | $-2.00B | · | · | · | $-3.00B | · | · | $-3.00B | · | |
| Dividends Paid | $175M | $162M | $162M | $163M | $162M | $149M | $149M | $150M | $149M | $135M | $136M | $135M | $117M | $117M | |
| Financing Cash Flow | $-1.57B | $1.09B | $3.53B | $-632M | $-991M | $-102M | $-3.67B | $-1.19B | $-115M | $-1.82B | $-1.43B | $1.85B | $-2.59B | $2.39B | |
| Net Change in Cash | $817M | $-6.60B | $7.87B | $-2.59B | $431M | $132M | $-630M | $-2.43B | $1.58B | $-2.58B | $1.93B | $3.02B | $-5.04B | $5.60B | |
| Free Cash Flow | · | $816M | · | · | · | $361M | · | · | · | $904M | · | · | $271M | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $605M | · | · | $-19M | · |
수익성 7
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 17.4% | 16.9% | · | 17.4% | 16.9% | 16.6% | · | 17.3% | 17.3% | 16.1% | · | 17.6% | 14.6% | · | |
| Net Margin | 14.5% | 15.0% | · | 14.5% | 14.9% | 14.6% | · | 15.4% | 14.7% | 12.9% | · | 16.0% | 12.1% | · | |
| Pretax Margin | 16.0% | 15.8% | · | 16.4% | 15.7% | 15.6% | · | 16.4% | 16.7% | 15.4% | · | 16.7% | 12.7% | · | |
| EBITDA Margin | 17.4% | 16.9% | · | 17.4% | 16.9% | 16.6% | · | 17.3% | 17.3% | 16.1% | · | 17.6% | 14.6% | · | |
| ROA | 1.6% | 1.6% | · | 1.6% | 1.6% | 1.5% | · | 1.7% | 1.6% | 1.4% | · | 1.8% | · | · | |
| ROE | 3.4% | 3.3% | · | 3.2% | 3.3% | 3.2% | · | 3.5% | 3.4% | 3.0% | · | 3.8% | · | · | |
| ROIC | 3.6% | 3.4% | · | 3.4% | 3.4% | 3.3% | · | 3.5% | 3.6% | 3.0% | · | 4.0% | · | · |
유동성 및 지급능력 3
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.5 | · | 1.5 | 1.9 | 1.8 | · | 1.6 | 1.7 | 1.7 | · | 1.6 | · | · | |
| Quick Ratio | 0.9 | 0.9 | · | 0.8 | 1.2 | 1.1 | · | 1.0 | 1.1 | 1.1 | · | 1.0 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 4.6 | · | 5.2 | 5.2 | · |
효율성 2
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | |
| Receivables Turnover | 1.3 | 1.2 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | · | · |
가치 평가 (TTM) 10
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $44.98B | $43.35B | · | $42.94B | $42.36B | $41.85B | · | $42.06B | $42.15B | $42.32B | · | $42.65B | $44.17B | · | |
| Net Income TTM | $6.62B | $6.39B | · | $6.37B | $6.31B | $6.02B | · | $6.20B | $5.94B | $5.68B | · | $5.85B | $6.68B | · | |
| Market Cap | $228.81B | $210.65B | · | $206.59B | $181.28B | $222.07B | · | $272.80B | $244.98B | $257.48B | · | $223.73B | · | · | |
| P/E | 29.1 | 27.9 | · | 27.7 | 24.7 | 31.8 | · | 38.0 | 35.8 | 39.5 | · | 33.7 | 34.0 | · | |
| P/S | 5.1 | 4.9 | · | 4.8 | 4.3 | 5.3 | · | 6.5 | 5.8 | 6.1 | · | 5.2 | · | · | |
| P/B | 4.3 | 4.1 | · | 4.0 | 3.6 | 4.5 | · | 5.6 | 5.2 | 5.7 | · | 4.9 | · | · | |
| P / Cash Flow | · | 176.7 | · | · | · | 307.2 | · | · | · | 205.8 | · | · | · | · | |
| P / FCF | · | 258.1 | · | · | · | 615.2 | · | · | · | 284.8 | · | · | · | · | |
| Earnings Yield | 3.4% | 3.6% | · | 3.6% | 4.0% | 3.1% | · | 2.6% | 2.8% | 2.5% | · | 3.0% | 2.9% | · | |
| Payout Ratio | · | 9.8% | · | · | · | 9.9% | · | · | · | 10.1% | · | · | 9.1% | · |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2025-06-28 | 2025-03-29 | 2024-12-31 | 2024-09-28 | |
|---|---|---|---|---|---|
| 매출 | $44.56B | — | — | $42.88B | — |
| 영업이익률 % | 17.4% | — | — | 17.1% | — |
| 순이익 | $6.70B | — | — | $6.33B | — |
| 희석 EPS | $17.74 | — | — | $16.53 | — |
대차대조표
| 2025-12-31 | 2025-06-28 | 2025-03-29 | 2024-12-31 | 2024-09-28 | |
|---|---|---|---|---|---|
| 유동비율 | 1.9 | — | — | 1.7 | — |
| 당좌 비율 | 1.3 | — | — | 1.0 | — |
현금 흐름
| 2025-12-31 | 2025-06-28 | 2025-03-29 | 2024-12-31 | 2024-09-28 | |
|---|---|---|---|---|---|
| 잉여현금흐름 | $6.29B | — | — | $7.27B | — |
최신 뉴스 이 회사 관련 최근 헤드라인
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 2,893개의 제출자 · $107.2B 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 196 (-6 이전 분기 대비) | 140 (-78 이전 분기 대비) | 925 (-41 이전 분기 대비) | 1,116 (+29 이전 분기 대비) | +59.7M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $12,171,173,789 | 24,276,316 | 11.35% | 주식 |
| STATE STREET CORP | $8,443,627,719 | 16,825,879 | 7.87% | 주식 |
| FMR LLC | $4,526,822,682 | 9,029,086 | 4.22% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $3,572,029,397 | 7,164,352 | 3.33% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $3,121,552,090 | 6,226,169 | 2.91% | 주식 |
| Capital World Investors | $3,106,193,041 | 6,195,370 | 2.90% | 주식 |
| NORGES BANK | $2,550,871,048 | 5,087,903 | 2.38% | 주식 |
| Capital Research Global Investors | $2,079,461,815 | 4,147,545 | 1.94% | 주식 |
| Capital International Investors | $1,595,416,232 | 3,182,151 | 1.49% | 주식 |
| Dodge & Cox | $1,531,543,498 | 3,054,778 | 1.43% | 주식 |
| Fisher Asset Management, LLC | $1,461,823,432 | 2,915,715 | 1.36% | 주식 |
| Grantham, Mayo, Van Otterloo & Co. LLC | $1,373,321,891 | 2,739,191 | 1.28% | 주식 |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $1,371,130,859 | 2,734,823 | 1.28% | 주식 |
| EdgePoint Investment Group Inc. | $1,092,789,324 | 2,179,650 | 1.02% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $1,046,130,256 | 2,086,585 | 0.98% | 주식 |
| Unisphere Establishment | $1,032,801,600 | 2,060,000 | 0.96% | 주식 |
| Mitsubishi UFJ Asset Management Co., Ltd. | $1,009,204,590 | 2,012,934 | 0.94% | 주식 |
| PRIMECAP MANAGEMENT CO/CA/ | $993,831,390 | 1,982,271 | 0.93% | 주식 |
| VIKING GLOBAL INVESTORS LP | $971,342,384 | 1,937,415 | 0.91% | 주식 |
| FLOSSBACH VON STORCH SE | $955,579,626 | 1,905,975 | 0.89% | 주식 |
| ALLIANCEBERNSTEIN L.P. | $908,857,157 | 1,849,037 | 0.85% | 주식 |
| 1832 Asset Management L.P. | $863,062,662 | 1,721,443 | 0.80% | 주식 |
| Clearbridge Investments, LLC | $847,834,531 | 1,691,069 | 0.79% | 주식 |
| PARNASSUS INVESTMENTS, LLC | $822,024,341 | 1,639,589 | 0.77% | 주식 |
| DIMENSIONAL FUND ADVISORS LP | $768,919,799 | 1,533,667 | 0.72% | 주식 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $667,185,605 | 1,330,750 | 0.62% | 주식 |
| Temasek Holdings (Private) Ltd | $583,447,171 | 1,163,729 | 0.54% | 주식 |
| BlackRock, Inc. | $579,344,543 | 1,155,546 | 0.54% | 주식 |
| LOOMIS SAYLES & CO L P | $571,001,278 | 1,138,905 | 0.53% | 주식 |
| LAZARD ASSET MANAGEMENT LLC | $567,301,499 | 1,131,525 | 0.53% | 주식 |
| Sumitomo Mitsui Trust Group, Inc. | $541,170,491 | 1,079,405 | 0.50% | 주식 |
| Pictet Asset Management Holding SA | $538,406,962 | 1,073,670 | 0.50% | 주식 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $526,019,392 | 1,049,185 | 0.49% | 주식 |
| Swiss National Bank | $525,485,443 | 1,048,120 | 0.49% | 주식 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $505,067,056 | 1,007,394 | 0.47% | 주식 |
| Rathbones Group PLC | $504,097,425 | 1,005,460 | 0.47% | 주식 |
| UBS Group AG | $503,596,066 | 1,004,460 | 0.47% | 주식 |
| BANK OF AMERICA CORP /DE/ | $488,690,042 | 974,729 | 0.46% | 주식 |
| WELLINGTON MANAGEMENT GROUP LLP | $450,916,165 | 899,386 | 0.42% | 주식 |
| Veritas Asset Management LLP | $442,637,207 | 882,873 | 0.41% | 주식 |
| Focus Partners Wealth | $431,444,332 | 860,536 | 0.40% | 주식 |
| FIRST MANHATTAN CO. LLC. | $422,447,886 | 841,894 | 0.39% | 주식 |
| National Pension Service | $422,118,548 | 841,947 | 0.39% | 주식 |
| GOLDMAN SACHS GROUP INC | $417,251,345 | 832,239 | 0.39% | 주식 |
| D1 Capital Partners L.P. | $409,672,787 | 817,123 | 0.38% | 주식 |
| W1M Asset Management Ltd | $408,009,352 | 814,886 | 0.38% | 주식 |
| Vanguard Global Advisers, LLC | $401,921,762 | 801,663 | 0.37% | 주식 |
| Legal & General Group Plc | $393,992,751 | 785,848 | 0.37% | 주식 |
| BARCLAYS PLC | $383,005,951 | 763,934 | 0.36% | 주식 |
| AMERIPRISE FINANCIAL INC | $373,268,191 | 744,431 | 0.35% | 주식 |
| BNP PARIBAS FINANCIAL MARKETS | $369,918,950 | 737,831 | 0.34% | 주식 |
| VANGUARD ASSET MANAGEMENT, Ltd | $365,892,528 | 729,800 | 0.34% | 주식 |
| VANGUARD GROUP INC | $354,408,424 | 611,629 | 0.33% | 주식 |
| California Public Employees Retirement System | $349,327,092 | 696,759 | 0.33% | 주식 |
| KING LUTHER CAPITAL MANAGEMENT CORP | $339,577,646 | 677,313 | 0.32% | 주식 |
| W1M Investment Management Ltd | $335,034,706 | 691,342 | 0.31% | 주식 |
| NEUBERGER BERMAN GROUP LLC | $321,963,477 | 642,176 | 0.30% | 주식 |
| RAYMOND JAMES FINANCIAL INC | $319,519,265 | 637,305 | 0.30% | 주식 |
| GLENVIEW CAPITAL MANAGEMENT, LLC | $314,473,046 | 627,240 | 0.29% | 주식 |
| VICTORY CAPITAL MANAGEMENT INC | $309,344,243 | 616,961 | 0.29% | 주식 |
| CANADA PENSION PLAN INVESTMENT BOARD | $307,944,336 | 614,218 | 0.29% | 주식 |
| D. E. Shaw & Co., Inc. | $307,017,322 | 612,369 | 0.29% | 주식 |
| JANUS HENDERSON GROUP PLC | $301,030,667 | 612,436 | 0.28% | 주식 |
| RHUMBLINE ADVISERS | $297,780,694 | 593,946 | 0.28% | 주식 |
| Ninety One UK Ltd | $297,641,362 | 593,668 | 0.28% | 주식 |
| ENVESTNET ASSET MANAGEMENT INC | $296,956,107 | 592,301 | 0.28% | 주식 |
| Mirova US LLC | $296,432,610 | 591,257 | 0.28% | 주식 |
| Robeco Institutional Asset Management B.V. | $289,599,072 | 577,627 | 0.27% | 주식 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $281,062,261 | 571,811 | 0.26% | 주식 |
| PRINCIPAL FINANCIAL GROUP INC | $274,562,786 | 547,636 | 0.26% | 주식 |
| Eurizon Capital SGR S.p.A. | $271,488,657 | 539,965 | 0.25% | 주식 |
| APG Asset Management N.V. | $266,543,464 | 607,825 | 0.25% | 주식 |
| Longview Partners (Guernsey) LTD | $265,608,495 | 529,776 | 0.25% | 주식 |
| CITADEL ADVISORS LLC | $263,486,238 | 525,543 | 0.25% | 주식 |
| Lindsell Train Ltd | $257,955,736 | 514,512 | 0.24% | 주식 |
| Southpoint Capital Advisors LP | $250,680,000 | 500,000 | 0.23% | 주식 |
| Qube Research & Technologies Ltd | $246,959,909 | 492,580 | 0.23% | 주식 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | $245,733,399 | 490,134 | 0.23% | 주식 |
| CI INVESTMENTS INC. | $235,771,058 | 470,263 | 0.22% | 주식 |
| Balyasny Asset Management L.P. | $225,425,494 | 449,628 | 0.21% | 주식 |
| VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. | $223,014,454 | 444,819 | 0.21% | 주식 |
| JONES FINANCIAL COMPANIES LLLP | $221,174,247 | 431,114 | 0.21% | 주식 |
| ROYAL LONDON ASSET MANAGEMENT LTD | $217,246,307 | 433,314 | 0.20% | 주식 |
| M&G PLC | $214,820,283 | 428,783 | 0.20% | 주식 |
| Liontrust Investment Partners LLP | $211,478,390 | 364,964 | 0.20% | 주식 |
| Cryder Capital Partners LLP | $210,160,586 | 419,181 | 0.20% | 주식 |
| FIFTH THIRD BANCORP | $209,624,364 | 418,112 | 0.20% | 주식 |
| JANE STREET GROUP, LLC | $205,206,648 | 409,300 | 0.19% | 풋 옵션 |
| JANE STREET GROUP, LLC | $204,905,832 | 408,700 | 0.19% | 콜 옵션 |
| Ensign Peak Advisors, Inc | $204,085,607 | 407,064 | 0.19% | 주식 |
| NEW YORK STATE COMMON RETIREMENT FUND | $203,978,817 | 406,851 | 0.19% | 주식 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $203,629,369 | 406,154 | 0.19% | 주식 |
| AVIVA PLC | $202,744,469 | 404,389 | 0.19% | 주식 |
| Navera Investment Management Ltd. | $199,087,273 | 397,439 | 0.19% | 주식 |
| FIL Ltd | $198,044,720 | 395,015 | 0.18% | 주식 |
| CIBC Bancorp USA Inc. | $190,068,606 | 378,891 | 0.18% | 주식 |
| Alyeska Investment Group, L.P. | $188,546,957 | 376,071 | 0.18% | 주식 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $187,568,351 | 373,510 | 0.17% | 주식 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $180,518,000 | 360,056 | 0.17% | 주식 |
| Railway Pension Investments Ltd | $179,973,199 | 358,970 | 0.17% | 주식 |
회사 내부자 60 명의 내부자 · 29 임원 · 28 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Marijn E Dekkers | Chief Executive Officer | 2009년 8월 17일 F | 42,554 | 0 | 0 | $0 |
| Stephen Williamson | Retiring Sr. VP and CFO | 2026년 2월 28일 F | 32,499 | 0 | 0 | $0 |
| Kyriazi Theo Melas | VP & Chief Financial Officer | 2004년 9월 16일 M | 158,199 | 0 | 0 | $0 |
| Gianluca Pettiti | President & COO | 2026년 7월 27일 S | 24,651 | 0 | 6 | $-2,582,704 |
| Mark Stevenson | Retiring Executive VP & COO | 2022년 2월 25일 F | 62,141 | 0 | 0 | $0 |
| Frederick M. Lowery | Executive Vice President | 2026년 2월 28일 F | 15,044 | 0 | 2 | $-8,154,131 |
| Michel Lagarde | Executive Vice President | 2026년 2월 28일 F | 85,151 | 0 | 5 | $-51,307,290 |
| Thomas B Shropshire Jr. | SVP and General Counsel | 2026년 2월 25일 A | 6,058 | 0 | 0 | $0 |
| Michael A Boxer | SVP and General Counsel | 2025년 3월 10일 S | 10,816 | 0 | 0 | $0 |
| Syed A. Jafry | Sr. Vice President | 2021년 2월 26일 F | 22,349 | 0 | 0 | $0 |
| Peter E Hornstra | VP & Chief Accounting Officer | 2021년 2월 26일 F | 1,962 | 0 | 0 | $0 |
| Patrick M Durbin | Senior Vice President | 2019년 8월 28일 F | 38,868 | 0 | 0 | $0 |
| Gregory J. Herrema | Senior Vice President | 2019년 8월 28일 F | 26,967 | 0 | 0 | $0 |
| Seth H Hoogasian | Sr. VP & Retiring Gen. Counsel | 2018년 2월 28일 F | 26,530 | 0 | 0 | $0 |
| Shine Daniel P | Senior Vice President | 2017년 8월 30일 S | 20,682 | 0 | 0 | $0 |
| Thomas W Loewald | Senior Vice President | 2017년 8월 28일 F | 38,133 | 0 | 0 | $0 |
| Peter M Wilver | Exec. VP & Chief Admin Officer | 2017년 3월 15일 S | 62,517 | 0 | 0 | $0 |
| Alan J Malus | Executive Vice President | 2016년 3월 10일 M | 47,286 | 0 | 0 | $0 |
| Andrew J Thomson | Senior Vice President | 2015년 8월 26일 F | 52,389 | 0 | 0 | $0 |
| Edward A Pesicka | Senior Vice President | 2015년 3월 5일 M | 80,641 | 0 | 0 | $0 |
| Kenneth Berger | Senior Vice President | 2012년 2월 26일 F | 36,128 | 0 | 0 | $0 |
| Stephen G Sheehan | Sr. VP, Human Resources | 2010년 3월 5일 F | 4,396 | 0 | 0 | $0 |
| Yuh-Geng Tsay | Senior Vice President | 2010년 2월 26일 F | 110,369 | 0 | 0 | $0 |
| Alexander G Stachtiaris | Sr. VP, Global Bus. Services | 2008년 3월 5일 A | 17,236 | 0 | 0 | $0 |
| Fredric T Walder | Sr. VP, Customer Excellence | 2008년 3월 5일 A | 16,730 | 0 | 0 | $0 |
| Guy Broadbent | Senior Vice President | 2008년 3월 5일 A | 31,545 | 0 | 0 | $0 |
| Joseph R Massaro | Sr. VP, Global Bus. Services | 2007년 11월 16일 S | 15,000 | 0 | 0 | $0 |
| SYRON RICHARD F/CA | Executive Chairman | 2003년 12월 12일 S | 80,320 | 0 | 0 | $0 |
| Barry S Howe | VP, Measurement & Control | 2003년 7월 31일 M | 23,247 | 0 | 0 | $0 |
| Alexandra R. Keith | 이사 | 2026년 6월 27일 A | 2,602 | 0 | 0 | $0 |
| Dion J Weisler | 이사 | 2026년 6월 27일 A | 5,446 | 0 | 0 | $0 |
| Karen S Lynch | 이사 | 2026년 6월 27일 A | 1,159 | 0 | 0 | $0 |
| Scott M Sperling | 이사 | 2026년 6월 27일 A | 69,479 | 0 | 0 | $0 |
| Jennifer M Johnson | 이사 | 2026년 6월 27일 A | 1,403 | 0 | 0 | $0 |
| Debora L Spar | 이사 | 2026년 5월 20일 A | 2,610 | 0 | 0 | $0 |
| Tyler Jacks | 이사 | 2026년 5월 20일 A | 9,462 | 0 | 0 | $0 |
| Ruby R Chandy | 이사 | 2026년 5월 20일 A | 3,463 | 0 | 0 | $0 |
| Nelson Chai | 이사 | 2026년 5월 20일 A | 15,316 | 0 | 0 | $0 |
| Martin C Harris | 이사 | 2026년 5월 20일 A | 9,532 | 0 | 0 | $0 |
| MULLEN JAMES C | 이사 | 2025년 5월 21일 A | 3,393 | 0 | 0 | $0 |
| Lars Rebien Sorensen | 이사 | 2024년 5월 22일 F | 9,233 | 0 | 0 | $0 |
| Jim P Manzi | 이사 | 2023년 2월 3일 S | 14,807 | 0 | 0 | $0 |
| Thomas J Lynch | 이사 | 2021년 11월 5일 G | 10,257 | 0 | 0 | $0 |
| Judy C Lewent | 이사 | 2020년 5월 20일 A | 1,290 | 0 | 0 | $0 |
| Elaine Ullian | 이사 | 2019년 5월 22일 A | 4,706 | 0 | 0 | $0 |
| William G Parrett | 이사 | 2018년 2월 23일 S | 11,660 | 0 | 0 | $0 |
| Michael E Porter | 이사 | 2012년 3월 9일 M | 14,640 | 0 | 0 | $0 |
| Peter J Manning | 이사 | 2011년 5월 25일 A | 6,548 | 0 | 0 | $0 |
| Michael Adam Bell | 이사 | 2010년 5월 20일 A | 8,192 | 0 | 0 | $0 |
| Stephen P Kaufman | 이사 | 2010년 5월 20일 A | 9,192 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 22 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Pharmaceutical Product Development, LLC, Wildcat Acquisition Holdings (UK) Limited, Jaguar Holding Company II, Jaguar Holding Company I, LLC, Eagle Holding Company II, LLC, PPD, Inc., Thermo Fisher Scientific Powder US Holdings Corp., Thermo Fisher Scientific Inc., Fisher Scientific International LLC, Fisher Scientific Worldwide Inc., Spectra-Physics Holdings USA, LLC, Thermo Fisher Scientific Powder Holdings I Ltd, Thermo Fisher Scientific Powder Holdings II Ltd, Thermo Fisher Scientific Powder Holdings III Ltd, Thermo Fisher Scientific Powder Holdings IV Ltd, Thermo Fisher Scientific Powder US Holdings Ltd ×2 제출 서류 | 2024년 3월 14일 | — | 최초 제출 | M&A / 매각 | SEC |
| Thermo Fisher Scientific Inc., Thermo Fisher (CN) Luxembourg S.à r.l. ×2 제출 서류 | 2017년 9월 13일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2005년 6월 30일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2005년 5월 11일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2005년 3월 24일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2005년 3월 2일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2004년 7월 28일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2004년 7월 27일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2003년 10월 28일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2002년 10월 17일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2002년 10월 16일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2002년 4월 4일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2002년 4월 1일 | — | 최초 제출 | — | SEC |
| Thermo Electron Corporation IRS No. ×5 제출 서류 | 2001년 12월 27일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2001년 11월 21일 | — | 최초 제출 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 213 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| GDOC · Goldman Sachs ETF Trust | 4.52% | 1,847 NS | 2026년 5월 31일 | N-PORT |
| AGIQ · Tidal Trust I | 3.99% | 918 NS | 2026년 5월 31일 | N-PORT |
| HRTS · Tema ETF Trust | 3.97% | 4,185 NS | 2026년 5월 31일 | N-PORT |
| IYH · iShares Trust | 3.51% | 222,608 SH | 2026년 8월 8일 | 일간 |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 3.19% | 740 NS | 2026년 4월 30일 | N-PORT |
| PRVS · Parnassus Funds II | 3.12% | 1,576 NS | 2026년 6월 30일 | N-PORT |
| QLTY · GMO ETF Trust | 2.94% | 269,227 NS | 2026년 5월 31일 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 2.91% | 173,204 NS | 2026년 4월 30일 | N-PORT |
| VHT · VANGUARD WORLD FUND | 2.74% | 1,117,168 SH | 2026년 8월 8일 | 일간 |
| IXJ · iShares Trust | 2.72% | 195,170 SH | 2026년 8월 8일 | 일간 |
| RXL · ProShares Trust | 2.68% | 3,918 NS | 2026년 5월 31일 | N-PORT |
| EQTY · Valued Advisers Trust | 2.66% | 72,927 NS | 2026년 4월 30일 | N-PORT |
| TOLL · Tema ETF Trust | 2.63% | 2,616 NS | 2026년 5월 31일 | N-PORT |
| CURE · Direxion Shares ETF Trust | 2.59% | 7,491 NS | 2026년 4월 30일 | N-PORT |
| QIDX · Spinnaker ETF Series | 2.39% | 1,916 NS | 2026년 4월 30일 | N-PORT |
| KAT · Advisors Series Trust | 2.24% | 30,779 NS | 2026년 3월 31일 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.99% | 2,213 NS | 2026년 4월 30일 | N-PORT |
| CAML · Professionally Managed Portfolios | 1.88% | 14,779 NS | 2026년 4월 30일 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.86% | 24,566 SH | 2026년 8월 8일 | 일간 |
| PEXL · Pacer Funds Trust | 1.67% | 1,592 NS | 2026년 4월 30일 | N-PORT |
| FMCE · Northern Lights Fund Trust IV | 1.64% | 2,250 NS | 2026년 5월 31일 | N-PORT |
| FMCX · Northern Lights Fund Trust IV | 1.63% | 3,902 NS | 2026년 5월 31일 | N-PORT |
| FMED · Fidelity Covington Trust | 1.53% | 1,276 NS | 2026년 5월 31일 | N-PORT |
| BKDV · BNY Mellon ETF Trust II | 1.43% | 41,397 NS | 2026년 4월 30일 | N-PORT |
| GKAT · Advisors Series Trust | 1.41% | 4,289 NS | 2026년 3월 31일 | N-PORT |
| RILA · Spinnaker ETF Series | 1.32% | 1,154 NS | 2026년 4월 30일 | N-PORT |
| SNPV · DBX ETF Trust | 1.26% | 5,900 NS | 2026년 5월 29일 | N-PORT |
| ALRG · ALLSPRING EXCHANGE-TRADED FUNDS TRU… | 1.22% | 189 NS | 2026년 4월 30일 | N-PORT |
| LRGC · AB Active ETFs, Inc. | 1.20% | 30,508 NS | 2026년 5월 31일 | N-PORT |
| EQWL · Invesco Exchange-Traded Fund Trust | 1.16% | 54,333 SH | 2026년 8월 8일 | 일간 |
| MFSG · MFS Active Exchange Traded Funds Tr… | 1.16% | 8,091 NS | 2026년 5월 31일 | N-PORT |
| RFFC · ALPS ETF Trust | 1.08% | 654 NS | 2026년 5월 31일 | N-PORT |
| FBCV · FIDELITY COVINGTON TRUST | 1.02% | 3,416 NS | 2026년 4월 30일 | N-PORT |
| FFND · Northern Lights Fund Trust II | 1.02% | 2,122 NS | 2026년 5월 31일 | N-PORT |
| MGV · VANGUARD WORLD FUND | 0.88% | 233,578 SH | 2026년 8월 8일 | 일간 |
| CAPE · DoubleLine ETF Trust | 0.86% | 4,580 NS | 2026년 3월 31일 | N-PORT |
| CRTC · DBX ETF Trust | 0.85% | 2,247 NS | 2026년 5월 31일 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0.84% | 15,398 NS | 2026년 4월 30일 | N-PORT |
| USXF · iShares Trust | 0.84% | 21,650 SH | 2026년 8월 8일 | 일간 |
| BSCQ · Invesco Exchange-Traded Self-Indexe… | 0.81% | 28,441,000 | 2026년 8월 8일 | 일간 |
| ZECP · Zacks Trust | 0.80% | 5,541 NS | 2026년 5월 31일 | N-PORT |
| IWX · iShares Trust | 0.79% | 54,993 SH | 2026년 8월 8일 | 일간 |
| TAX · EA Series Trust | 0.79% | 408 NS | 2026년 5월 29일 | N-PORT |
| BIGY · Tidal Trust II | 0.75% | 409 NS | 2026년 4월 30일 | N-PORT |
| OEI · Listed Funds Trust | 0.75% | 656 NS | 2026년 4월 30일 | N-PORT |
| IVE · iShares Trust | 0.72% | 615,615 SH | 2026년 8월 8일 | 일간 |
| FFLC · FIDELITY COVINGTON TRUST | 0.72% | 16,950 NS | 2026년 4월 30일 | N-PORT |
| JOYT · J.P. Morgan Exchange-Traded Fund Tr… | 0.71% | 1,284 NS | 2026년 4월 30일 | N-PORT |
| VTV · VANGUARD INDEX FUNDS | 0.70% | 3,534,266 SH | 2026년 8월 8일 | 일간 |
| IUSV · iShares Trust | 0.68% | 322,866 SH | 2026년 8월 8일 | 일간 |